Varenicline Tartrate



Varenicline Tartrate





(var en’ ah klin)

Chantix

PREGNANCY CATEGORY C


Drug Classes

Nicotine receptor agonist

Smoking deterrent



Therapeutic Actions

Selectively binds with specific neuronal nicotinic acetylcholine receptors; acts as an agonist at these sites while preventing nicotine binding to these receptors. This mechanism is thought to aid in smoking cessation.


Indications



  • Aid to smoking cessation treatment



Available Forms

Capsules—0.5, 1 mg


Dosages

Adults

Patient should pick a date to stop smoking and begin drug therapy 1 wk before that date; or patient can begin drug and quit smoking between days 8 and 35 of treatment.

Days 1–3, 0.5 mg/day PO; days 4–7, 0.5 mg PO bid; day 8 until the end of treatment, 1 mg PO bid. Drug should be taken after eating with a full glass of water. Treatment should last 12 wk; patients who successfully quit smoking in that time may benefit from another 12 wk to increase the likelihood of long-term abstinence. Patients who fail to quit smoking during the 12 wk or who relapse after treatment can be treated again when factors leading to failed attempt have been identified and addressed.

Pediatric patients

Safety not established for children younger than 18 yr.

Patients with severe renal impairment

Initially, 0.5 mg/day PO; titrate to 0.5 mg PO bid. If on dialysis, 0.5 mg/day.

Jul 21, 2016 | Posted by in NURSING | Comments Off on Varenicline Tartrate

Full access? Get Clinical Tree

Get Clinical Tree app for offline access